Radioligand Therapy Targets by Cancer Type
Radioligand therapy needs a target that sits on the tumor cell surface, is expressed in most patients, and is spared in dose-limiting organs. Pick a cancer type to see which proteins meet the bar.
| Cancer type | Cell-surface candidates | Known RLT targets expressed |
|---|---|---|
| Prostate Cancer | 4,031 | PSMA, EPCAM, B7-H3, HER3 |
| Neuroendocrine Tumors | 3,865 | HER3, c-MET, STEAP2, SSTR2 |
| Lung Cancer | 4,217 | EPCAM, HER3, CEA, EGFR |
| Pancreatic Cancer | 4,357 | HER3, FAP, STEAP2, c-MET |
| Breast Cancer | 4,328 | HER3, FAP, STEAP2, B7-H3 |
| Ovarian Cancer | 4,405 | EPCAM, STEAP2, HER3, c-MET |
| Colorectal Cancer | 4,339 | EPCAM, HER3, CEA, c-MET |
| Kidney Cancer | 3,966 | EGFR, HER3, c-MET, ITGAV |
| Bladder Cancer | 4,316 | HER3, ITGAV, EGFR, Nectin-4 |
| Gastric Cancer | 4,158 | HER3, CEA, FAP, c-MET |
| Liver Cancer | 4,436 | EGFR, STEAP2, HER3, c-MET |
| Glioma | 3,815 | EGFR, HER3, ITGAV, B7-H3 |
| Melanoma | 4,224 | HER3, STEAP2, B7-H3, c-MET |
| Head and Neck Cancer | 3,879 | EGFR, ITGAV, HER3, B7-H3 |
| Thyroid Cancer | 4,106 | EPCAM, c-MET, ITGAV, STEAP2 |
| Lymphoma | 3,396 | CD20, CD45, CD19, c-MET |
| Cervical Cancer | 4,191 | HER3, c-MET, ITGB6, EGFR |
| Endometrial Cancer | 4,207 | EPCAM, HER3, B7-H3, ITGAV |
| Skin Cancer | 3,878 | B7-H3, EGFR, HER3, c-MET |
| Testicular Cancer | 4,013 | HER3, STEAP2, c-MET, KIT |
Looking for a specific protein? Browse all target profiles.
Data sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.